These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37698736)

  • 1. N
    Wang Y; Jin P; Wang X
    Apoptosis; 2024 Feb; 29(1-2):142-153. PubMed ID: 37698736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N
    Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
    Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N6-methyladenosine reader protein IGF2BP1 suppresses CD8 + T cells-mediated tumor cytotoxicity and apoptosis in colon cancer.
    Peng Y; Zhang Z; Yang G; Dai Z; Cai X; Liu Z; Yun Q; Xu L
    Apoptosis; 2024 Apr; 29(3-4):331-343. PubMed ID: 37848671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. circATAD2 mitigates CD8
    Zhang Z; Huo W; Li J
    Cancer Immunol Immunother; 2024 May; 73(7):130. PubMed ID: 38748254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumour immunity controlled through mRNA m
    Han D; Liu J; Chen C; Dong L; Liu Y; Chang R; Huang X; Liu Y; Wang J; Dougherty U; Bissonnette MB; Shen B; Weichselbaum RR; Xu MM; He C
    Nature; 2019 Feb; 566(7743):270-274. PubMed ID: 30728504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts antitumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis.
    Wang L; Zhu L; Liang C; Huang X; Liu Z; Huo J; Zhang Y; Zhang Y; Chen L; Xu H; Li X; Xu L; Kuang M; Wong CC; Yu J
    J Hepatol; 2023 Nov; 79(5):1185-1200. PubMed ID: 37459919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WTAP-induced N
    Liu QZ; Zhang N; Chen JY; Zhou MJ; Zhou DH; Chen Z; Huang ZX; Xie YX; Qiao GL; Tu XH
    Cancer Sci; 2024 Jun; 115(6):1749-1762. PubMed ID: 38508217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evodiamine impairs HIF1A histone lactylation to inhibit Sema3A-mediated angiogenesis and PD-L1 by inducing ferroptosis in prostate cancer.
    Yu Y; Huang X; Liang C; Zhang P
    Eur J Pharmacol; 2023 Oct; 957():176007. PubMed ID: 37611839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N
    Tang B; Bi L; Xu Y; Cao L; Li X
    Mol Biotechnol; 2023 Oct; ():. PubMed ID: 37817028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pumilio1 regulates NPM3/NPM1 axis to promote PD-L1-mediated immune escape in gastric cancer.
    Wang H; Zhou Z; Zhang J; Hao T; Wang P; Wu P; Su R; Yang H; Deng G; Chen S; Gu L; He Y; Zeng L; Zhang C; Yin S
    Cancer Lett; 2024 Jan; 581():216498. PubMed ID: 38029539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N
    Wan W; Ao X; Chen Q; Yu Y; Ao L; Xing W; Guo W; Wu X; Pu C; Hu X; Li Z; Yao M; Luo D; Xu X
    Mol Cancer; 2022 Feb; 21(1):60. PubMed ID: 35197058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ELK1-mediated YTHDF1 drives prostate cancer progression by facilitating the translation of Polo-like kinase 1 in an m6A dependent manner.
    Li P; Shi Y; Gao D; Xu H; Zou Y; Wang Z; Li W
    Int J Biol Sci; 2022; 18(16):6145-6162. PubMed ID: 36439881
    [No Abstract]   [Full Text] [Related]  

  • 14. Methionine deficiency facilitates antitumour immunity by altering m
    Li T; Tan YT; Chen YX; Zheng XJ; Wang W; Liao K; Mo HY; Lin J; Yang W; Piao HL; Xu RH; Ju HQ
    Gut; 2023 Mar; 72(3):501-511. PubMed ID: 35803704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LRPPRC facilitates tumor progression and immune evasion through upregulation of m
    Wang H; Tang A; Cui Y; Gong H; Li H
    Front Immunol; 2023; 14():1144774. PubMed ID: 37063837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.
    Yu ZZ; Liu YY; Zhu W; Xiao D; Huang W; Lu SS; Yi H; Zeng T; Feng XP; Yuan L; Qiu JY; Wu D; Wen Q; Zhou JH; Zhuang W; Xiao ZQ
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non-small-cell lung cancer.
    Tsuchiya K; Yoshimura K; Inoue Y; Iwashita Y; Yamada H; Kawase A; Watanabe T; Tanahashi M; Ogawa H; Funai K; Shinmura K; Suda T; Sugimura H
    Oncoimmunology; 2021; 10(1):1962656. PubMed ID: 34408926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination.
    Sun Z; Mai H; Xue C; Fan Z; Li J; Chen H; Huo N; Kang X; Tang C; Fang L; Zhao H; Han Y; Sun C; Peng H; Du Y; Yang J; Du N; Xu X
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The m
    Diao H; Tan H; Hu Y; Wang R; Cai P; Huang B; Shao X; Yan M; Yin C; Zhang Y
    Pharmaceuticals (Basel); 2023 Jan; 16(2):. PubMed ID: 37259333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting m
    Bao Y; Zhai J; Chen H; Wong CC; Liang C; Ding Y; Huang D; Gou H; Chen D; Pan Y; Kang W; To KF; Yu J
    Gut; 2023 Aug; 72(8):1497-1509. PubMed ID: 36717220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.